<section style="max-width:1100px;margin:0 auto;padding:48px 20px;font-family:system-ui,-apple-system,BlinkMacSystemFont,Segoe UI,Roboto;">
  
  <h1 style="font-size:2rem;font-weight:800;margin-bottom:12px;">
    How Levels Are Specified
  </h1>

  <p style="max-width:860px;color:#374151;font-size:1.05rem;margin-bottom:28px;">
    Risk Continuum assigns a <b>management level</b> based on biologic burden, plaque status,
    and the degree of uncertainty that remains after available data are considered.
    Treatment intensity increases only when risk signals are dominant, converging,
    or disease is present.
  </p>

  <!-- Validation Table -->
  <div style="overflow-x:auto;">
    <table style="width:100%;border-collapse:collapse;font-size:0.95rem;">
      <thead>
        <tr style="background:#f9fafb;">
          <th style="text-align:left;padding:10px;border-bottom:2px solid #e5e7eb;">Level</th>
          <th style="text-align:left;padding:10px;border-bottom:2px solid #e5e7eb;">Risk state</th>
          <th style="text-align:left;padding:10px;border-bottom:2px solid #e5e7eb;">What qualifies</th>
          <th style="text-align:left;padding:10px;border-bottom:2px solid #e5e7eb;">Medication posture</th>
        </tr>
      </thead>
      <tbody>

        <!-- LEVEL 1 -->
        <tr>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;"><b>Level 1</b></td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">Minimal risk signal</td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            No established atherosclerotic disease and no dominant biologic risk driver.<br>
            ApoB &lt;100 mg/dL (or LDL-C &lt;130 if ApoB unavailable); no diabetes-range signal,
            no smoking, no inflammatory disease driving risk.
          </td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            ‚ùå Lifestyle-first. No escalation.
          </td>
        </tr>

        <!-- LEVEL 2A -->
        <tr>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;"><b>Level 2A</b></td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">Emerging (isolated)</td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            Exactly one mild signal without convergence, such as:
            ApoB 80‚Äì99 mg/dL, LDL-C 100‚Äì129 mg/dL (if ApoB not measured),
            prediabetes-range A1c, isolated hsCRP ‚â•2 mg/L,
            or premature family history alone.
          </td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            ‚ùå Do not treat routinely. Complete data, lifestyle sprint, reassess.
          </td>
        </tr>

        <!-- LEVEL 2B -->
        <tr>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;"><b>Level 2B</b></td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">Emerging (converging)</td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            Mild signals are converging, defined by:
            ‚â•2 Level-2A signals, <i>or</i> ASCVD PCE ‚â•7.5% with plaque unmeasured,
            <i>or</i> one mild signal plus missing key clarifiers (ApoB or Lp(a)).
          </td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            üü° Treatment reasonable. Preference-sensitive after clarification.
          </td>
        </tr>

        <!-- LEVEL 3A -->
        <tr>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;"><b>Level 3A</b></td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">Actionable biology</td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            At least one major actionable biologic driver present
            (ApoB ‚â•100 mg/dL, LDL-C ‚â•130 mg/dL if ApoB unavailable,
            diabetes-range A1c, current smoking, inflammatory disease),
            <b>without additional accelerators</b>.
          </td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            üü† Therapy reasonable. Timing preference-sensitive.
          </td>
        </tr>

        <!-- LEVEL 3B -->
        <tr>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;"><b>Level 3B</b></td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">Actionable biology + enhancers</td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            Actionable biology <b>plus ‚â•1 accelerator</b>:
            elevated Lp(a), premature family history,
            chronic inflammatory disease, diabetes-range signal,
            or current smoking.
          </td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            üü† Therapy generally favored unless strong reason to defer.
          </td>
        </tr>

        <!-- LEVEL 4 -->
        <tr>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;"><b>Level 4</b></td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">Subclinical atherosclerosis</td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            Atherosclerotic plaque present on imaging
            (CAC 1‚Äì99) without clinical ASCVD.
          </td>
          <td style="padding:10px;border-bottom:1px solid #e5e7eb;">
            üî¥ Treat as early disease. Target-driven lipid lowering.
          </td>
        </tr>

        <!-- LEVEL 5 -->
        <tr>
          <td style="padding:10px;"><b>Level 5</b></td>
          <td style="padding:10px;">Very high risk / ASCVD</td>
          <td style="padding:10px;">
            Clinical ASCVD <b>or</b> high plaque burden (CAC ‚â•100).
          </td>
          <td style="padding:10px;">
            üî¥ Secondary-prevention intensity. Maximize tolerated therapy.
          </td>
        </tr>

      </tbody>
    </table>
  </div>

  <!-- CAC Callout -->
  <div style="margin-top:32px;padding:18px;border-left:4px solid #2563eb;background:#f8fafc;">
    <h3 style="margin-top:0;">Coronary Calcium (CAC)</h3>
    <p style="margin:0;">
      CAC is <b>never recommended routinely</b>. It is a tie-breaker only when plaque is unmeasured:
      obtain CAC only if a score of 0 would delay therapy or a positive score would prompt initiation
      or intensification. If CAC is already known (CAC = 0 or CAC positive), CAC messaging is suppressed.
    </p>
  </div>

  <p style="margin-top:24px;color:#6b7280;font-size:0.9rem;">
    This specification mirrors the Risk Continuum engine logic exactly and is intended
    for validation, transparency, and shared clinical understanding.
  </p>

</section>
